Product No.：C100006
English Name：(2'S,3'R)-Cabazitaxel
English Alias：(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2S,3R)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate
CAS No.：1714967-27-7
Molecular Formula：C₄₅H₅₇NO₁₄
Molecular Weight：835.93
As a stereoisomeric impurity of Cabazitaxel, this product features high purity and well-defined structure, which can be used for optimization of drug synthesis processes, quality research, and stability evaluation, facilitating precise control of stereochemical impurities in pharmaceutical development.
Primarily used for quality control research of the anticancer drug Cabazitaxel, including:
As a reference standard for methodological validation of analytical methods such as HPLC and NMR;
Evaluating the efficiency of stereoselective reactions and impurity generation risks in drug production processes;
Supporting the assessment of impurity safety and tolerance in drug registration applications.
Cabazitaxel is a taxane-based chemotherapy drug that exerts anticancer effects by inhibiting microtubule depolymerization, clinically used for treating castration-resistant prostate cancer and other solid tumors. (2'S,3'R)-Cabazitaxel, as a key chiral impurity, may originate from epimerization at chiral centers during synthesis. Its presence may affect the drug's efficacy and safety, making research on this impurity a critical component of the drug quality system.
Current research on chiral impurities of taxane drugs mainly focuses on the following directions:
Developing highly sensitive stereoselective analytical methods (such as chiral HPLC and supercritical fluid chromatography) for precise impurity quantification;
Investigating the metabolic pathways and toxicological characteristics of impurities in vivo to establish safety thresholds;
Reducing impurity formation through process optimization (such as using chiral catalysts or kinetic resolution techniques).
Structural confirmation and activity studies of this impurity have been initiated in some pharmaceutical research institutions, but published literature on its specific toxicity data and clinical impacts remains limited, requiring further in-depth investigation.
China
